论文部分内容阅读
目的探讨经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果。方法选取2014年2月至2016年1月76例膀胱癌患者,按不同的手术治疗方法分为观察组和对照组,各38例。所有患者均行经尿道电切术,观察组采用吉西他滨进行膀胱灌注,对照组采用吡柔比星进行膀胱灌注。比较两组患者治疗后的生存质量、复发率、生存率和不良反应发生情况。结果治疗前两组患者生存质量评分差异无统计学意义(P>0.05),治疗后观察组患者生存质量评分显著高于对照组(P<0.01)。观察组1年、2年复发率均显著低于对照组,1年、2年生存率均显著高于对照组(P<0.05,P<0.01)。观察组各不良反应发生率均低于对照组(P<0.05,P<0.01)。结论经尿道电切术联合吉西他滨灌注治疗膀胱癌能显著改善患者的生存质量,且复发率低,生存率高,不良反应少。
Objective To investigate the clinical effect of transurethral resection combined with gemcitabine infusion in the treatment of bladder cancer. Methods Sixty-six patients with bladder cancer from February 2014 to January 2016 were selected and divided into observation group and control group according to different operation methods, 38 cases in each group. All patients underwent transurethral resection of the urethra. The observation group received intravesical instillation of gemcitabine and the control group received intravesical instillation of pirarubicin. The quality of life, relapse rate, survival rate and adverse reactions of the two groups were compared after treatment. Results There was no significant difference in quality of life between the two groups before treatment (P> 0.05). After treatment, the quality of life score of the observation group was significantly higher than that of the control group (P <0.01). The recurrence rates at 1 year and 2 years in the observation group were significantly lower than those in the control group, and the 1-year and 2-year survival rates were significantly higher in the observation group than those in the control group (P <0.05, P <0.01). The incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05, P <0.01). Conclusions Transurethral resection combined with gemcitabine infusion can significantly improve the quality of life of patients with low recurrence rate, high survival rate and few adverse reactions.